MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS (oHSV) AND METHODS OF USE THEREOF
AssigneeThe General Hospital Corporation
InventorsRobert L. Martuza, Samuel D. Rabkin, Dipongkor Saha, Nusrat Jahan
Life of this patent
Estimating the term…
Abstract
Described herein is an oncolytic herpes simplex virus, G47ΔhIL12A, which is G47Δ containing a cassette expressing a transgene, e.g., human IL-12, driven by a spontaneously arising genetically altered HCMV immediate-early (IE) enhancer/promoter. This virus has augmented (A) production of the transgene and increased virus replication while retaining safety. Also provided are methods of use thereof for treating cancer, e.g., glioblastoma (GBM) and triple-negative breast cancer (TNBC).
Claims43
An expression cassette comprising an enhancer sequence comprising two or more DR2 repeat sequence units (CGCTCCTCCCCC (SEQ ID NO:7) inserted upstream of a promoter, preferably within 500, 250, 200, or 100 nucleotides of the promoter, and optionally a transgene operably linked to the promoter.
An oncolytic herpes simplex virus (oHSV) comprising a promoter and an enhancer sequence, wherein the enhancer sequence comprises from six to 24 DR2 repeat sequence units (CGCTCCTCCCCC (SEQ ID NO:7), preferably wherein the enhancer sequence comprises:
- (SEQ ID NO:
- 4)
- CTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCG
- CTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCC
- CCGCTCCTCCCCCCGCTCCTCCCCCCCCCGCTCCCGCGGCCCCGC
- CCCCAACGCCCGCTCCTCCCCCCGCTCCCGCGGCCCCGCCC,
- or
- (SEQ ID NO:
- 5)
- CTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCG
- CTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCC
- CCGCTCCTCCCCCCGCTCCTCCCCCCCCCGCTCCCGCGGCCCCGC
- CCCCAACGCCCGCTCCTCCCCCCGCTCCCGCGGCCCCGCCCCCAA
- CGCCCGCCGCGCGCGCGCACGCCGCCCTTGACTCACGGGGATTTC
- CAAGTCTCCACCCCATTGACGTC,
- or
- (SEQ ID NO:
- 15)
- ATCCCCCGCTCCTCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCT
- CCTCCCCCCGCTCCTCCCCCGCTCCTCCCCCCGCTCCTCCCCCCG
- CTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCC
- CCGCTCCTCCCCCCGCTCCCGCGGCCCCGCCCCCAACGCCCGCTC
- CTCCCCCCGCTCCCGCGGCCCCGCCCCCAACGCCCGCCGCGCGCG
- CGCACGCCGCCCGGACCGCCGCCCGCCTTTTTTGCGCGCCGCCCC
- GCCCGCGGGGGGCCCGGGCTGCGCCGCCGCGCTTTAAAGGGCCGC
- GCGCGACCCCCGGGGGGTGTGTTTCGGGGGGGGCCCGTTTCTCCC
- GCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCC
- CCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCT
- CCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCT
- CCCGCGGCCCCGCCCCCAACGCCCGCTCCTCCCCCCGCTCCCGCG
- GCCCCGCCCCCAACGCCCGCCGCGCGCGCGCACGCCGCCCT.
An oncolytic herpes simplex virus (oHSV) comprising a promoter and an enhancer sequence comprising:
- (SEQ ID NO:
- 16)
- CTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCG
- CTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCC
- CCGCTCCTCCCCCCGCTCCTCCCCCCCCCGCTCCCGCGGCCCCGC
- CCCCAACGCCCGCTCCTCCCCCCGCTCCCGCGGCCCCGCCCCCAA
- CGCCCGCCGCGCGCGCGCACGCCGCCCTTGACTCACGGGGATTTC
- CAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACC
- AAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCAT
- TGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAA
- GCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTA
- TCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTTACCGGC
- GAAGGAGGGCCACC.
An oHSV comprising a human IL-12 expression cassette comprising SEQ ID NO:17, optionally wherein the oHSV is G47Δ.
A method of treating glioblastoma in a subject, the method comprising administering to the subject a G47Δ oncolytic herpes simplex virus (oHSV) comprising a promoter and an enhancer sequence, wherein the enhancer sequence comprises from six to 24 DR2 repeat sequence units (CGCTCCTCCCCC (SEQ ID NO:7), preferably wherein the enhancer and promoter sequence comprises SEQ ID NO:16, in combination with an anti-PD-1 antibody and an anti-CTLA-4 antibody.
A method of treating glioblastoma in a subject, the method comprising administering to the subject an oncolytic herpes simplex virus (oHSV) comprising a promoter and an enhancer sequence, wherein the enhancer sequence comprises from six to 24 DR2 repeat sequence units (CGCTCCTCCCCC (SEQ ID NO:7), preferably wherein the enhancer and promoter sequence comprises SEQ ID NO:16, in combination with an anti-PD-1 antibody and an anti-CTLA-4 antibody.
Dependencies are inferred from the claim text.